These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10259800)

  • 1. Pharmaceutical Reimbursement Board; final maximum allowable cost (MAC) determinations for certain drug products--Health Care Financing Administration. Final notice.
    Fed Regist; 1982 Dec; 47(251):58370-2. PubMed ID: 10259800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical Reimbursement Board; suspension of maximum allowable cost limits on specific drug products--HCFA.
    Fed Regist; 1983 Sep; 48(191):44931. PubMed ID: 10262646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Reimbursement Board; rinal maximum allowable cost (MAC) determinations for certain drug products--HCFA. Final notice for maximum allowable cost determinations.
    Fed Regist; 1982 Jun; 47(124):27968-73. PubMed ID: 10261467
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceutical Reimbursement Board; maximum allowable cost (MAC) limits and announcement of public hearing--HCFA. Proposed notice.
    Fed Regist; 1982 May; 47(104):23570-2. PubMed ID: 10261465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Financing Administration: Pharmaceutical Reimbursement Board; final maximum allowable cost determinations.
    Fed Regist; 1979 Aug; 44(169):50651-6. PubMed ID: 10297564
    [No Abstract]   [Full Text] [Related]  

  • 6. MAC regulations: their predicted economic impact on pharmaceutical reimbursement.
    Gammill CG; Francis WR
    Contemp Pharm Pract; 1981; 4(1):32-6. PubMed ID: 10298086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare and Medicaid programs; rural health clinic payment limits and productivity screening guidelines; correction--Health Care Financing Administration. Correction of final notice.
    Fed Regist; 1983 Feb; 48(29):6177. PubMed ID: 10298962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare program; list of covered surgical procedures for certain ambulatory surgical services--Health Care Financing Administration. Final notice.
    Fed Regist; 1982 Aug; 47(151):34099-101. PubMed ID: 10317271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare and Medicaid programs; schedules of guidelines for physical therapy and respiratory therapy services. Health Care Financing Administration. Notice.
    Fed Regist; 1982 Mar; 47(59):13047. PubMed ID: 10298466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare program; Provider Reimbursement Review Board decision on the lack of jurisdiction--Health Care Financing Administration. Notice of HCFA ruling.
    Fed Regist; 1982 Dec; 47(232):54302-5. PubMed ID: 10298953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare and Medicaid programs; limits on payments for drugs--HCFA. Final rule.
    Fed Regist; 1987 Jul; 52(147):28648-58. PubMed ID: 10301766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare and Medicaid programs, less than effective drugs. Health Care Financing Administration. Notice of legislation affecting implementation and enforcement of interim final rule.
    Fed Regist; 1982 Jan; 47(8):1386. PubMed ID: 10298360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare program; Provider Reimbursement Review Board: expedited administrative review--Health Care Financing Administration. Final rule with comment period.
    Fed Regist; 1982 Jul; 47(141):31686-91. PubMed ID: 10298787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicaid program; prescription drugs. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Jul; 72(136):39141-245. PubMed ID: 17674494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare and Medicaid programs; less than effective drug products subject to a notice of opportunity for hearing; correction--Health Care Financing Administration. Correction of general notice.
    Fed Regist; 1981 Oct; 46(210 Pt 2):54304-11. PubMed ID: 10298332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare program; provider reimbursement determinations and appeals. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 May; 73(101):30189-267. PubMed ID: 18605405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicaid program; time limitation on price recalculations and recordkeeping requirements under the drug rebate program. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Aug; 68(168):51912-7. PubMed ID: 12962118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare program; annual update to reasonable compensation equivalent limits for services furnished by physicians to providers--HCFA. Final notice with comment period.
    Fed Regist; 1985 Feb; 50(34):7123-31. PubMed ID: 10299897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical reimbursement and drug cost control: the MAC experience in Maryland.
    Sawyer DO
    Inquiry; 1983; 20(1):76-87. PubMed ID: 6219949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.